View Financial HealthPyxis Oncology 배당 및 자사주 매입배당 기준 점검 0/6Pyxis Oncology 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.5%자사주 매입 수익률총 주주 수익률-0.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesPyxis Oncology, Inc., Annual General Meeting, Jun 15, 2026May 04Pyxis Oncology Presents New Preclinical Data on MICVO Combination Therapy in HNSCC ModelApr 18New major risk - Financial position Mar 24Full year 2025 earnings: EPS and revenues exceed analyst expectations Mar 24Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026Feb 04+ 1 more updateNew minor risk - Market cap size Dec 21Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaDec 18New major risk - Share price stability Dec 03Pyxis Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Nov 26Price target increased by 10% to US$6.63 Nov 05Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025Oct 10Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) Sep 12New major risk - Financial position Sep 04Pyxis Oncology, Inc. Announces Revisions to Patient Enrollment Participants Related to Phase 1 Monotherapy Clinical TrialAug 04Pyxis Oncology, Inc. Announces CFO Changes, Effective July 1, 2025Jul 03+ 1 more updatePyxis Oncology, Inc.(NasdaqGS:PYXS) dropped from Russell 2500 Value IndexJun 30+ 10 more updatesHere's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn SituationJun 19Pyxis Oncology, Inc., Annual General Meeting, Jun 18, 2025Apr 30Pyxis Oncology, Inc. Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-In-Concept Extracellular-Targeting ADCApr 26Pyxis Oncology, Inc. Reduces its Workforce by Approximately 20%Mar 18+ 1 more updatePyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck CancerFeb 26Pyxis Oncology, Inc. Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy TrialFeb 05New major risk - Shareholder dilution Jan 15Price target decreased by 17% to US$8.83 Jan 12Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201Dec 20New minor risk - Market cap size Dec 08Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead Dec 07New minor risk - Share price stability Nov 21Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 DataNov 21Moment Of Truth Approaches For Pyxis Oncology Sep 13Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of DirectorsJun 13Pyxis Oncology: Promising Research Amid Cash Constraints Jun 10Consensus revenue estimates increase by 258%, EPS downgraded May 21Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice PresidentMay 15Price target increased by 11% to US$8.00 May 07Pyxis Oncology, Inc., Annual General Meeting, Jun 11, 2024Apr 28Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait Mar 28New major risk - Shareholder dilution Mar 24Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of DirectorsMar 13Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investorsFeb 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis Jan 18Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical OfficerNov 29Price target decreased by 40% to US$6.00 Nov 12CEO, President & Director recently sold US$63k worth of stock Sep 15Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.Aug 24+ 1 more updatePrice target decreased by 19% to US$8.67 Aug 17High number of new and inexperienced directors Aug 04Price target decreased by 19% to US$8.67 Jun 14Chief Medical Officer notifies of intention to sell stock Jun 11New minor risk - Market cap size Jun 10Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical ProgramsMay 31Pyxis Oncology, Inc. (NasdaqGS:PYXS) entered into a definitive agreement to acquire Apexigen, Inc. (NasdaqCM:APGN) for $15.9 million.May 26Pyxis Oncology, Inc. Announces Resignation of Jay M. Feingold as Chief Medical Officer, Effective June 15, 2023May 25Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?Feb 18Price target decreased to US$11.00 Nov 16High number of new and inexperienced directors Nov 16Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn SituationSep 01Pyxis Oncology, Inc. Appoints Rachel Humphrey to Its Board of DirectorsAug 16Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06 Aug 15Pyxis Oncology, Inc. Appoints Jitendra Wadhane as Chief Accounting Officer and Principal Accounting OfficeAug 11Pyxis Oncology, Inc.(NasdaqGS:PYXS) dropped from Russell 2500 Value IndexJun 26+ 2 more updatesHigh number of new and inexperienced directors May 02High number of new and inexperienced directors Apr 27Pyxis Oncology Announces Leadership ChangesApr 14We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash WiselyApr 13High number of new and inexperienced directors Jan 01Independent Director recently bought US$94k worth of stock Dec 11Independent Director recently bought US$200k worth of stock Nov 20지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PYXS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PYXS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Pyxis Oncology 배당 수익률 vs 시장PYXS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PYXS)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.6%분석가 예측 (PYXS) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PYXS 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PYXS 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PYXS 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PYXS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/04 16:58종가2026/05/04 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pyxis Oncology, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tazeen AhmadBofA Global ResearchBradley CaninoGuggenheim Securities, LLCSwayampakula RamakanthH.C. Wainwright & Co.9명의 분석가 더 보기
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026Feb 04+ 1 more update
Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaDec 18
Pyxis Oncology, Inc. Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets, Effective October 9, 2025Oct 10
Pyxis Oncology, Inc. Announces Revisions to Patient Enrollment Participants Related to Phase 1 Monotherapy Clinical TrialAug 04
Pyxis Oncology, Inc. Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-In-Concept Extracellular-Targeting ADCApr 26
Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck CancerFeb 26
Pyxis Oncology, Inc. Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy TrialFeb 05
Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201Dec 20
Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investorsFeb 28
Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.Aug 24+ 1 more update
Pyxis Oncology, Inc. (NasdaqGS:PYXS) entered into a definitive agreement to acquire Apexigen, Inc. (NasdaqCM:APGN) for $15.9 million.May 26
Pyxis Oncology, Inc. Announces Resignation of Jay M. Feingold as Chief Medical Officer, Effective June 15, 2023May 25
Pyxis Oncology, Inc. Appoints Jitendra Wadhane as Chief Accounting Officer and Principal Accounting OfficeAug 11